Topical Mometasone

  title={Topical Mometasone},
  author={Amitabh Prakash and Paul Benfield},
SummarySynopsisMometasone, a synthetic 16α-methyl analogue of beclomethasone, is classified as a ‘potent’ glucocorticoid for dermatological use. It is available as 0.1% cream, ointment and lotion formulations for the treatment of patients with inflammatory glucocorticoid-responsive dermatoses.In patients with atopic dermatitis, the effects of mometasone 0.1% applied once daily over 2 to 3 weeks were similar to those of other glucocorticoids of similar potency, such as betamethasone dipropionate… 
Mometasone furoate 0.1 % ointment and hydrogel: a guide to their use in corticosteroid-responsive dermatoses
In the treatment of moderate-to severe psoriasis, eczema and atopic dermatitis, the efficacy of mometasone furoate 0.1 % ointment applied once daily was greater than, or similar to, that of several other potent corticosteroids applied twice or three times daily.
Efficacy, safety and tolerability of mometasone furoate 0.1% cream, ointment and lotion in childhood eczema
Mometasone furoate 0.1% cream, ointment and lotion are found to be effective, safe and highly tolerable in childhood eczema and the compound was found equally safe in infants.
An open label study to compare the efficacy of topical mometasone furoate with topical placental extract versus topical mometasone furoate with topical tacrolimus in patients with vitiligo involving less than 10% body surface area.
Topical Tacrolimus 0.1% ointment could be better option for the treatment of localized vitiligo when compared to topical placental extract but in combination with a steroid cream.
Mometasone Furoate
Intranasal mometasone furoate improved the nasal symptoms of SAR and PAR to a significantly greater extent than placebo as determined by reductions from baseline in patient- and/or investigator-assessed total nasal symptom scores (TNSS).
Strategies for using topical corticosteroids in children and adults with eczema
The effectiveness and safety of different ways of using topical corticosteroids for treating eczema are established and abnormal skin thinning is prioritised as a key area of concern for healthcare professionals and patients.
Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery
SLNs proved the potential for topical delivery of corticosteroid drug over the conventional formulations and can be prepared, which would help in increasing skin deposition as well as provide sustained release.
Efficacy of Elaeagnus angustifolia Topical Gel in the Treatment of Symptomatic Oral Lichen Planus
The results suggest that 19% EA gel is efficient in the treatment of symptomatic oral lichen planus, with anti-inflammatory and analgesic effects, as well.
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study
It is demonstrated that the beneficial effect of SLIT with high or medium dose D. farinae Drops on AD, and the treatment was well tolerated, is demonstrated.
Modern approaches to the classification of topical glucocorticosteroidsin Russia and abroad
The article analyzes current classifications of topical glucocorticosteroid drugs. It also describes advantages and disadvantages of current classifications, emphasizes the expediency of assessing


Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
Mometasone ointment and cream provide a highly effective once-a-day treatment for moderate to severe psoriasis with minimal risk of side effects.
Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis.
Once-Daily 0.1% Mometasone Furoate Cream versus Twice-Daily 0.1% Betamethasone Valerate Cream in the Treatment of a Variety of Dermatoses
It was concluded that mometasone furoate was as effective as betamethasone valerate in the treatment of a variety of steroid-responsive dermatoses, although momet asone f Kuroate was applied only half as frequently.
While mometasone furoate is found to be a highly effective treatment for a variety of steroid‐responsive dermatoses, this drug has only a limited potential for production of local and systemic side effects, so a high margin of safety can be expected for patients using this drug.
Mometasone furoate cream 0.1% vs. hydrocortisone cream 1% in the treatment of seborrhoeic dermatitis
The safety and efficacy of mometasone furoate cream 0.1% (applied once daily), and hydrocortisone cream 1% (applied twice. daily) were compared in a 6-week multicentre, randomized, third-party-blind,
In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Evidence of an increased benefit-risk ratio as compared to previous medium potent topical glucocorticoids is given, of particular interest facing psoriasis vulgaris where an antiproliferative activity of a drug is needed.
Mometasone versus betamethasone creams: a trial in dermatoses.
Mometasone furoate cream 0.1% applied daily in dermatoses is as effective as betamethasone valerate 0.
Topical mometasone furoate and betamethasone‐17‐valerate decrease collagen synthesis to a similar extent in human skin in vivo
It is concluded that MMF and BM‐17‐valerate decrease collagen synthesis to the same extent in human skin in vivo.